Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBF 1120 in Recurrent Glioblastoma
NCT01251484Phase 2Completed
- Sponsor
- Lassen Therapeutics
- Start
- Jan 2011
- Primary completion
- Aug 2012
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of nintedanib in glioblastoma multiforme (GBM) (2 arms), sponsored by Lassen Therapeutics. Primary endpoint: Response Rate. Started Jan 2011; status: completed.
02
Drugs
nintedanib
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT01251484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01251484.